Prosecution Insights
Last updated: September 21, 2026

Miralogx LLC

6 pending office actions • 0 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready

Portfolio Summary

6
Total Pending OAs
6
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (17%)
3
Medium (50%)
2
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (17%)
§102 only2 (33%)
§112 only2 (33%)
Multi-statute (no §101)1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
6
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SCHMIDT, IZABELA MARIA 1 66.0% +44.5%
MAHLUM, JONATHAN DAVIS 1 51.4% +20.5%
RAO, SAVITHA M 1 60.7% +30.2%
LEESER, ERICH A 1 81.7% +13.4%
CORNET, JEAN P 1 42.1% +47.5%
VALLE, ERNESTO 1 56.7% +37.9%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18755178 Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods LEESER, ERICH A —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19034034 Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders SCHMIDT, IZABELA MARIA —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
19034034 Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders SCHMIDT, IZABELA MARIA —
18891706 ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS MAHLUM, JONATHAN DAVIS —
18832143 Anticancer Compounds, Pharmaceutical Compositions, and Methods of Treating Cancers RAO, SAVITHA M —
18755178 Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods LEESER, ERICH A —
18721001 Anti-inflammatory Compounds, Pharmaceutical Compositions, and Treatment Methods CORNET, JEAN P —
18673060 Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders VALLE, ERNESTO —

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19034034 Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders SCHMIDT, IZABELA MARIA — §103§112 Non-Final OA — Pending Jan 22, 2025
18891706 ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS MAHLUM, JONATHAN DAVIS — §112 Non-Final OA — Pending Sep 20, 2024
18832143 Anticancer Compounds, Pharmaceutical Compositions, and Methods of Treating Cancers RAO, SAVITHA M — §102Other Non-Final OA — Pending Jul 23, 2024
18755178 Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods LEESER, ERICH A — §103 Non-Final OA — Pending Jun 26, 2024
18721001 Anti-inflammatory Compounds, Pharmaceutical Compositions, and Treatment Methods CORNET, JEAN P — §112 Non-Final OA — Pending Jun 17, 2024
18673060 Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders VALLE, ERNESTO — §102 Non-Final OA — Pending May 23, 2024

Managing Miralogx LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month